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Structured Summary 
Background: Sepsis is one of the leading causes of death in the UK.  
 
Aims: The aims of this study were to identify the rate of inactive antimicrobial 
therapy (AMT) in the ICU and whether inactive AMT had an effect on in hospital 
mortality, ICU mortality, 90-day mortality and length of hospital stay.  Additionally, we 
wanted to identify risk factors for receiving inactive AMT. 
 
Methods: This was a retrospective observational study conducted at Glasgow Royal 
Infirmary ICU between January 2010 and December 2013, with 12,000 blood 
cultures taken over this time period, of which n=127 were deemed clinically 
significant.  Multivariate logistic regression was used to identify risk factors 
independently associated with mortality. To identify risk factors for receiving inactive 
AMT a univariable and a subsequent multivariate analysis was constructed.  
 
Results: The rate of inactive AMT was 47% (n =60).  Our multivariate analysis 
showed that receiving antibiotics within the first 24 hours of ICU admission led to a 
reduced mortality (RR 1.70; 95% CI 1.19-2.44.) Furthermore, it showed that severity 
of illness (as defined by SIRS criteria sepsis vs septic shock) increased mortality 
(OR 9.87; 95% CI 1.73-55.5). However, inactive AMT did not increase mortality (OR 
1.07; 95% CI 0.47-2.41) or length of hospital stay (53.2 vs 69.1 days p=0.348.) We 
identified fungal bloodstream infection as a risk factor for receiving inactive AMT (OR 
5.10;95% CI 1.29-20.14) 
 
Conclusion: Mortality from sepsis is influenced by multiple factors. We were unable 
to demonstrates that inactive AMT had an effect on mortality in sepsis. 
 
Keywords : Sepsis, Intensive care, Bacteraemia, Antibiotics, Organism, Fungal 
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Introduction 
 
Blood-stream infection (BSI) can have a mortality in the intensive care unit (ICU) of 
up to 70%1. Antimicrobial therapy (AMT) is a cornerstone for treating patients with 
suspected infection – the Surviving Sepsis Campaign recommends initiating AMT 
within the first hour of recognition of sepsis2. However, empiric AMT started for the 
suspicion of infection in the ICU may be inactive in over 1 in 5 cases3. A positive 
impact of empiric AMT that is active against the infecting organism in ICU patients 
has not been consistently demonstrated, with some authors finding that it improves 
survival in severe sepsis/septic shock 4–6 whilst others have concluded that it makes 
no difference7–9. Few studies have assessed the impact of adequate antimicrobial 
therapy on length of stay in the ICU 10,11. Finally, the factors that increase the risk of 
ICU patients receiving inactive AMT are not well known; identifying these could 
reduce exposure to inappropriate antimicrobials and healthcare costs. 
 
The aims of this study were to determine the effect of inactive antimicrobial therapy 
on the mortality of patients in intensive care with BSI and to identify risk factors for 
receiving inactive AMT in such patients.  
 
Methods 
 
Study setting 
This study was a retrospective observational study of prospectively gathered data 
undertaken in the intensive care unit of Glasgow Royal Infirmary (GRI), a 20 bed 
mixed surgical-medical ICU admitting 1000 patients annually.  
 
Patients 
All patients who had at least one blood culture drawn between 1st Jan 2010-31st Dec 
2013 were identified from microbiological records. No patients admitted for specific 
conditions or with comorbidities were excluded. Only the index positive culture 
episode, consisting of all cultures taken at the initial drawing of blood, was evaluated. 
 
Definitions 
Definitions of sepsis were in line with the criteria established by Bone et al. 12   
Bacteraemia was defined as the growth of a viable organism in a blood culture taken 
from a patient during their ICU stay. Organisms commonly considered to be 
contaminants – coagulase-negative staphylococci, Propionibacterium acnes and 
Corynebacterium spp – were considered true infections only if isolated from a patient 
in two or more consecutive cultures taken on different days. Coagulase-negative 
staphylococci were not identified to the species level.  In all cases of coagulase 
negative staphylococcal bacteraemia this was due to line infection. 
Bacteraemia identified within <48 hours of a patient being admitted to hospital was 
considered community acquired. Patients admitted from wards, operating theatre or 
another hospital were considered to have nosocomial bacteraemia.  
Empiric therapy was defined as agents that were started before a positive blood 
culture, and the antimicrobial susceptibility of the isolated organism, was identified. If 
it had in vitro activity against the isolated pathogen(s), the AMT was considered 
active. Other authors have used this approach. 8,13 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Patients who were on no antimicrobial therapy were included in the inactive cohort.  
Antimicrobial sensitivity testing was carried out using the automated broth 
microdilution Vitek ® 2 system from BioMérieux. 
 
Study design 
Demographic, clinical and microbiological data were gathered from eligible patients, 
including isolated organism(s), time and number of cultures and antimicrobial 
therapy at time culture, from WardWatcher (Critical Care Audit Limited, West 
Yorkshire, UK) and CareVue (Philips Medical Systems, Surrey, UK). The empiric 
AMT of all patients was reviewed by a clinical microbiologist prior to their records 
being included in this study.   
 
Statistical analysis 
Continuous variables were compared using Student’s t-test or the Mann-Whitney U 
test for continuous variables and categorical variables Pearson chi-square test. 
Univariate factors with a p-value of <0.2 were entered into a multivariate logistic 
regression model along with the outcome variable to determine factors 
independently associated with increased mortality.  
To identify risk factors for receiving inactive AMT a multivariate analysis was 
constructed as above, with ‘inappropriate AMT’ as the outcome variable. A p-value of 
<0.05 was considered significant. Data were analysed using Statistical Package for 
the Social Sciences (SPSS) version 22.0 (SPSS, Chicago, IL).  
 
Results 
 
Study population 
Over the study period, 1083/3759 patients admitted to the ICU had blood cultures 
taken.  Positive blood culture episodes were identified in 207 (19.1%) patients, of 
which 127 were considered clinically significant and could have empiric 
antimicrobials assessed.  
 
Patient characteristics and presentation 
The mean age was 55.8 years (SD 15.5) and the mean APACHE II score was 22.7 
(SD 8).  Seventy-two patients (57%) were male and 14 (11%) had a previous ICU 
admission. Fifty-eight patients (46%) were classified as a medical admission, 77 
patients (61%) had received antimicrobials prior to ICU admission whilst 91 patients 
(72%) received antimicrobial therapy within two days of ICU admission. At the index 
positive culture episode, 20 patients (16%) met criteria for sepsis, 55 (43%) for 
severe sepsis and 52 (41%) for septic shock.  Of all admissions, 42 (33%) patients 
were admitted from the emergency department or from operating theatres having not 
resided previously in hospital.  Twenty-one of these had a time between admission 
and positive culture episode of ≤2 days and were thus classified as community 
acquired bacteraemia, with 106 cases (84%) classified as nosocomial bacteraemia.  
The median time to a positive culture from ICU admission was 2.0 days (IQR 0-7).  
 
Antimicrobial therapy 
Sixty patients (47%) had inactive empiric AMT; in 43 cases (72%) this was due to the 
patient either being on no therapy when the positive culture was taken or because 
the therapy they were on had no intrinsic activity against the organism isolated 
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(‘wrong’ antibiotics).  The remaining 17 cases received an antibiotic to which the 
organism was resistant. 
 
Microbiology 
A breakdown of the organisms isolated from all cultures making up the index positive 
episodes is available in Table I. Table II shows the breakdown of these organisms by 
AMT exposure status. The total number of isolates exceeding the number of 
patients/blood culture episodes assessed is due to patients having multiple sets of 
cultures drawn simultaneously (for example from an indwelling line and peripherally, 
or two peripheral cultures) and polymicrobial isolates. Fifty-nine patients (46%) had 
two or more cultures from different sites positive with the same organism(s). Nine 
patients (7%) had cultures positive for two or more clinically significant organisms 
(polymicrobial).  Of the remaining unimicrobial episodes, 66 (52%) were gram 
negative, 44 (35%) were gram positive and ten (8%) were fungal. The most 
commonly isolated organisms were Staphylococcus aureus (16%, n=33) and 
Escherichia coli (19%, n=39). 
 
Mortality 
Sixty-eight patients (54%) did not survive to hospital discharge. Within the active 
AMT group, 37 (55%) patients did not survive, compared to 31 (52%) in the inactive 
AMT group.  Table II provides a breakdown of active vs inactive AMT by organisms 
isolated. Risk factors for in-hospital mortality are shown in Table III.  In the univariate 
analysis patients who died had significantly higher APACHE II scores and were more 
severely ill. Community acquired bacteraemia was also associated with a higher risk 
of death. Receiving antibiotics within 24 hours of ICU admission and having a 
surgical reason for admission were both protective factors. No specific 
microorganisms were associated with greater mortality (data not shown).  Inactive 
empiric therapy was not associated with an increased in-hospital mortality.  This held 
true when stratifying by severity of infection or analyzing only cases due to 
resistance (RR 0.88, 95% CI 0.71-1.09) or no intrinsic activity (RR 1.19 95% CI 0.88-
1.61). Subgroup analyses did not demonstrate greater mortality with inactive AMT in 
any specific group. 
 
The results of multivariate logistic regression for ICU, in-hospital and 90-day 
mortality are listed in Table IV.  The only factor independently associated with 
increased in-hospital mortality was severity of illness (septic shock vs sepsis OR 
9.87 (95% CI 1.73-55.5)).  Inactive AMT did not independently increase in-hospital 
mortality, (OR 1.07 (0.47-2.41)).  
 
Length of stay 
In patients who survived to hospital discharge, there was no significant difference in 
length of stay between those who received active or inactive empiric AMT (53.2 vs 
69.1 days, p=0.348).  
 
Risk factors for inactive empiric antimicrobial therapy 
We also analysed the 60 patients who received initially inactive therapy and 
compared to them to the patients who received active therapy. In a multivariate 
analysis, only the presence of a fungal infection (OR 5.10; 95% CI 1.29-20.14) was 
independently associated with receiving inactive AMT.  
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Discussion 
 
A number of factors have been shown to increase mortality in sepsis including 
immunosuppression, age, illness severity, high APACHE II score, delay in receiving 
AMT, and hospital acquired sepsis. 9,14  Our study showed that septic shock was 
associated with increased mortality (OR 5.24 (1.35-20.36)) whereas receiving 
antibiotics within 24 hours of ICU admission led to a reduced mortality (RR 0.79; 
95% CI 0.65-0.98).  This emphasises the importance of recognising sepsis early and 
instituting treatment as per the Surviving Sepsis Campaign. 2,15  
 
In the univariate analysis, we found that mortality was greatest with a higher 
APACHE II score (24.4 in non-survivors vs 20.8 in survivors, p=0.011) and in 
community acquired bacteraemia (RR 5.21; 95% CI 1.61-16.80). The higher 
mortality with community acquired bacteraemia contrasts with others who have 
found that patients with hospital acquired bacteraemia have a higher mortality. 14,16 
We found that the community acquired patients had a higher APACHE II score (26 
vs 21 p=0.04); met more SIRS criteria at time of culture (3.1 vs 2.5 p=0.01) and a 
higher proportion of these patients were in septic shock at time of culture (62% vs 
37% p=0.06).  Therefore, our community acquired bacteraemia group had a greater 
severity of illness than the hospital acquired group. 
 
We defined therapy as active if the antimicrobial(s) the patient was on when a culture 
was flagged as positive were effective against the isolated organism. This included 
fungal organisms and patients receiving no therapy which may explain why our rate 
of inactive therapy is higher than reported elsewhere although comparing rates of 
inactive AMT is problematic due to varying definitions. Some studies defined AMT as 
active if empiric therapy was active prior to organism identification and sensitivity 
results; here rates of inactive AMT of 8.5% 17 and 23.5% 8 were found . Marshcall et 
al and Kang et al defined AMT as active if given within 24 hours of sampling with 
rates of inactive AMT of 31.6% 18 and 52.8% 9 respectively. The rate of inactive AMT 
by Garnacho-Montero et al was 17% and they defined it as adequate based on the 
patients’ admission antibiotics to ICU. 11 Varying definitions of ‘inactive’ therapy likely 
contribute to different studies of the impact of inactive AMT reaching opposing 
results. 
 
Our results demonstrated that septic shock increases mortality, however we did not 
find that inactive AMT affects mortality or length of stay. This was a surprising finding 
given our own observation that receiving antibiotics within 24 hours of admission 
reduced mortality. A high proportion of our population (84%) met criteria for severe 
sepsis or septic shock at time of positive culture, implying that they were 
experiencing some form of organ dysfunction. Whilst antimicrobials are essential for 
treating the initiating/underlying infection, it is likely they have less of an effect on the 
immune dysregulation and subsequent organ dysfunction that characterise sepsis. In 
these cases, factors such as intensive organ support available in ICU, comorbidities, 
age and underlying genetics probably have a far greater prognostic influence. When 
we analysed mortality with inactive AMT by severity of infection, we found no 
difference. We believe this supports our theory that by the time patients have 
developed sepsis or shock, immunological and genetic factors primarily determine 
outcome. Additionally, organisms such as enterococci or coagulase negative 
staphylococci comprised a high proportion of isolates; it is possible that this ‘diluted’ 
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excess mortality caused by more pathogenic isolates such as Pseudomonas 
species, and thus reduced the observable mortality benefits of antimicrobial therapy. 
We analysed the impact of inactive AMT stratified by organism, however no 
differences between subgroups was found, likely because the numbers available 
were simply too small for an effect to be detected. Organisms such as S. aureus can 
produce toxins that may increase mortality that other low virulence organisms such 
as coagulase negative staphylococci do not.  Whilst with S. aureus no effect on 
mortality has been found for Panton-Valentine leucocidin toxin producing strains or 
superantigen producing strains, there has been a potential link with increased 
mortality and cytotoxic exotoxin producing strains19. 
 
Our laboratory uses the Vitek ® 2 system for antimicrobial sensitivity testing. Broth 
microdilution systems have reported higher MIC’s for piperacillin/tazobactam than 
agar dilution methods for Escherichia coli and therefore potentially overcall 
resistance. 20 Users of the Vitek ® 2 during our study period have reported higher 
piperacillin/tazobactam MIC’s from the system than with manual Etests for gram 
negative organisms.  Our study period overlaps with the period when resistance 
testing was potentially inaccurate, however; none of the patients who received 
inactive AMT were on piperacillin/tazobactam monotherapy. 
 
Previous antibiotic exposure 11,17, antibiotic resistant bacteria 5,  Pseudomonas 7, 
hospital acquired infection 5,7 and fungal infection 5,11 have all been identified as risk 
factors for inactive AMT. Our study only identified fungal infection as a risk factor for 
inactive AMT (OR 5.10; 95% CI 1.29-20.14.)  ICU patients will often have risk factors 
for fungal infection such as invasive catheters, immune-compromise or GI surgery21. 
Clinicians may not assess for these risk factors and therefore do not think of 
antifungal cover as part of their antimicrobial escalation regimes when patients 
deteriorate.  Because of this study we will now assess patients for risk factors for 
candidaemia.  
 
This study had several weaknesses that need to be considered. Firstly, the efficacy 
of dosing of antibiotics was not assessed and this is particularly relevant for 
antibiotics such as aminoglycosides. AMT was assessed to be active or inactive at 
the time blood culture sensitivities were known; we did not assess the impact on 
mortality of changes to AMT therapy made once a positive culture was flagged up, 
which is a potential confounder. Finally, our study was conducted with a relatively 
small sample size in a single centre.  
 
 
Conclusions 
  
Sepsis/shock caused by bacteraemia in the intensive care population will comprise a 
small, but significant and resource intensive proportion of sepsis cases in hospitals. 
Such patients will have multiple factors influencing prognosis. We have 
demonstrated that in our patient cohort, inactive empiric therapy compared with 
active empiric antimicrobial therapy did not affect outcome measures. Further insight 
in future studies by use of greater stratification of patient cohorts, particularly by 
causative infective agent would be helpful. Our findings underline the complexities 
when assessing active empiric antimicrobial efficacy and outcome in all cases of 
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sepsis. Finally, we identified candidaemia as a risk factor for receiving inactive 
antimicrobial therapy.  
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Table IV - Multivariate logistic regression for risk factors associated with ICU, in-
hospital and 90 day mortality in intensive care patients with sepsis caused by blood 
stream infection 
 
Risk factor ICU mortality In-hospital mortality 90 day mortality 
 OR (95% CI) 
APACHE II 1.03 (0.97-1.09) 1.04 (0.98-1.10) 1.04 (0.98-1.11) 
Age 0.99 (0.96-1.02) 1.00 (0.98-1.03) 1.01 (0.98-1.04) 
Admission type    
PS* vs Medical 0.55 (0.17-1.79) 0.50 (0.16-1.57) 0.53 (0.17-1.67) 
US+ vs Medical 0.92 (0.36-2.32) 0.77 (0.30-1.96) 1.22 (0.47-3.18) 
US vs PS 1.67 (0.48-5.81) 1.53 (0.47-4.99) 2.28 (0.70-7.40) 
Nosocomial BSI# 0.63 (0.25-1.61) 0.53 (0.21-1.35) 0.56 (0.21-1.44) 
Antibiotics within 
24 hours of ICU 
admission 
0.35 (0.25-0.89) 0.51 (0.20-1.37) 0.41 (0.15-1.13) 
Severity of illness    
Severe sepsis 1.92 (0.47-8.00) 2.88 (0.76-10.89) 2.79 (0.79-9.85) 
Septic shock 1.93 (1.31-23.2) 5.24 (1.35-20.36) 3.89 (1.06-14.30) 
Inactive AMT$ 1.35 (0.61-3.11) 1.07 (0.47-2.41) 0.99 (0.44-2.24) 
* PS: planned surgical 
+US: unplanned surgical 
#BSI: blood-stream infection 
$AMT: antimicrobial therapy 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table I- Organisms isolated from index positive blood cultures 
 
Gram positive  
Staphylococcus aureus 33 
Coagulase-negative Staphylococci 20 
Enterococcus spp. 31 
Clostridium spp. 2 
Streptococcus pneumonia  1 
Other Streptococcus spp.  2 
Gram negative  
Escherichia coli 39 
Klebsiella spp.  23 
Pseudomonas spp. 10 
Enterobacter spp.  7 
Proteus mirabilis 2 
Acinetobacter baumannii 2 
Citrobacter braakii 2 
Stenotrophomonas maltophilia 1 
Aeromonas hydrophilia 2 
Morganella morganii 2 
Serratia marcescens 4 
Burkholderia cepacia 2 
Fungi  
Candida albicans 16 
Other Candida spp. 4 
Saccharomyces cervisiae 2 
Total 207 
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Table II- List of organisms that were exposed to active antimicrobial therapy and 
inactive antimicrobial therapy 
 
Inactive AMT Active AMT 
Gram positive 
Clostridium spp. 2 Clostridium spp. 2 
Enterococcus spp. 19 Enterococcus spp. 12 
S. aureus 13 S. aureus 20 
CNS 12 CNS 8 
Streptococcus 
pneumoniae 1 
Streptococcus 
pneumoniae 1 
Other strep spp. 0 Other strep spp. 2 
Gram negative 
Enterobacter spp. 3 Enterobacter spp. 4 
Pseudomonas spp. 3 Pseudomonas spp. 7 
Acinetobacter spp. 2 Acinetobacter spp. 0 
E coli  6 E coli  33 
Klebsiella spp. 5 Klebsiella spp 18 
Stenotrophomonas 1 Stenotrophomonas 0 
Proteus spp. 2 Proteus spp. 0 
Morganella spp. 2 Morganella spp. 0 
Serratia spp. 4 Serratia spp. 0 
Burkholderia spp. 2 Burkholderia spp. 0 
Citrobacter spp. 0 Citrobacter spp. 1 
Aeromonas spp. 0 Aeromonas spp. 1 
Fungi 
Candida albicans 11 Candida albicans 5 
Other candida spp 4 Other candida spp 0 
Saccharomyces 0 Saccharomyces 2 
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Table III- Univariate analysis of risk factors for in hospital mortality in intensive care 
patients with sepsis caused by blood stream infection 
 
Factor Survivors Nonsurvivors RR (95% CI) P-value 
Age 53.4 58.6 - 0.086 
APACHE II 20.8 24.4 - 0.011 
Gender (female) 24 31 1.12 (0.75-1.68)  
Antibiotics within 48 
hours of ICU 
47 44 0.79 (0.65-0.98)  
Admission type 
    
Medical 21 37 1  
Planned surgical 18 9 0.42 (0.22-0.83)  
Unplanned surgical 19 22 0.78 (0.49-1.25)  
CCI* score 
    
0 17 16 1  
1-2 22 25 1.08 (0.75-1.56)  
≥3 19 27 1.18 (0.81-1.75)  
Severity of infection 
    
Sepsis 15 5 1  
Severe sepsis 28 27 1.30 (0.99-1.69)  
Septic shock 16 36 1.70 (1.19-2.44)  
Community 
acquired 
bacteraemia 
3 18 5.21 (1.61-16.80)  
Inactive AMT (all) 29 31 1.07 (0.7-1.49)  
Inactive AMT 
(sepsis) 
7 3 0.75 (0.23-2.42)  
Inactive AMT 
(severe sepsis) 
15 10 1.35 (0.83-2.22)  
Inactive AMT (septic 
shock) 
7 18 0.88 (0.52-1.53)  
Gram negative 
organisms 
    
Sepsis (inactive; 
n=6/12) 
4 2 5.00 (0.29-86.4)  
Severe sepsis 
(inactive; n=10/31) 
8 2 0.32 (0.09-1.17)  
Septic shock 
(inactive; n=7/21) 
2 5 0.93 (0.55-1.59)  
Individual organisms 
    
Enterococcus spp. 
(inactive; n=10/13) 
3 7 2.10 (0.40-10.94)  
E coli (inactive; 
n=4/27) 
1 3 0.41 (0.07-2.31)  
Klebsiella spp. 
(inactive; n=5/16) 
3 2 0.73 (0.22-2.45)  
Pseudomonas 
spp.(inactive; n=3/9) 
2 1 0.25 (0.05-1.36)  
Staphylococcus 
aureus (inactive; 
n=11/21) 
6 5 1.13 (0.42-3.10)  
*Charlson Comorbidity Index score 
 
